The stock of AngioDynamics, Inc. (NASDAQ:ANGO) hit a new 52-week high and has $23.62 target or 36.00% above today’s $17.37 share price. The 5 months bullish chart indicates low risk for the $659.15 million company. The 1-year high was reported on Oct, 3 by Barchart.com. If the $23.62 price target is reached, the company will be worth $237.29M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 107,858 shares traded hands. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 61.36% since February 29, 2016 and is uptrending. It has outperformed by 49.15% the S&P500.
Analysts await AngioDynamics, Inc. (NASDAQ:ANGO) to report earnings on October, 13. They expect $0.13 earnings per share, up 18.18% or $0.02 from last year’s $0.11 per share. ANGO’s profit will be $4.93 million for 33.40 P/E if the $0.13 EPS becomes a reality. After $0.19 actual earnings per share reported by AngioDynamics, Inc. for the previous quarter, Wall Street now forecasts -31.58% negative EPS growth.
AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage
Out of 5 analysts covering AngioDynamics (NASDAQ:ANGO), 1 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 20% are positive. AngioDynamics has been the topic of 7 analyst reports since July 24, 2015 according to StockzIntelligence Inc. Zacks upgraded AngioDynamics, Inc. (NASDAQ:ANGO) on Monday, August 31 to “Sell” rating. The firm has “Buy” rating given on Friday, January 8 by Canaccord Genuity. The company was downgraded on Tuesday, April 5 by Canaccord Genuity. The firm has “Mkt Perform” rating by Raymond James given on Tuesday, November 10. Sidoti initiated AngioDynamics, Inc. (NASDAQ:ANGO) rating on Wednesday, September 23. Sidoti has “Neutral” rating and $14.50 price target. The rating was reinitiated by Piper Jaffray with “Neutral” on Friday, April 8. The firm has “Overweight” rating by KeyBanc Capital Markets given on Friday, July 24.
According to Zacks Investment Research, “AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company’s diverse product line includes angiographic products and accessories, dialysis products, vascular access products, PTA products, drainage products, thrombolytic products and venous products.”
Insitutional Activity: The institutional sentiment increased to 1.87 in Q2 2016. Its up 0.50, from 1.37 in 2016Q1. The ratio is positive, as 11 funds sold all AngioDynamics, Inc. shares owned while 20 reduced positions. 10 funds bought stakes while 48 increased positions. They now own 24.22 million shares or 1.02% less from 24.47 million shares in 2016Q1.
The Florida-based Rgm Cap Limited Liability Company has invested 5.85% in AngioDynamics, Inc. (NASDAQ:ANGO). C M Bidwell And Associates holds 0.03% or 7,555 shares in its portfolio. Panagora Asset Mngmt holds 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO) for 31,077 shares. American Cap holds 0.1% or 84,000 shares in its portfolio. Teacher Retirement System Of Texas holds 0% or 3,791 shares in its portfolio. Perkins Capital accumulated 44,850 shares or 0.74% of the stock. New York State Teachers Retirement Systems holds 0% or 14,386 shares in its portfolio. Citigroup Inc, a New York-based fund reported 15,633 shares. California Pub Employees Retirement System holds 0% or 102,800 shares in its portfolio. Hutchin Hill Limited Partnership holds 0.01% or 16,300 shares in its portfolio. Ahl Prtn Limited Liability Partnership holds 17,579 shares or 0.01% of its portfolio. The Illinois-based Northern has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Gamco Et Al, a New York-based fund reported 66,000 shares. Connor Clark & Lunn Invest Mngmt Limited has invested 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). Natl Bank Of America De last reported 0% of its portfolio in the stock.
Insider Transactions: Since April 21, 2016, the stock had 0 buys, and 4 sales for $65.86 million net activity. Avista Capital Partners GP – LLC had sold 2.24 million shares worth $32.76 million on Friday, August 5. Greiner Charles R sold $43,183 worth of stock. On Friday, August 5 the insider Burgstahler David F sold $32.90 million. Trowbridge Stephen A sold $159,184 worth of AngioDynamics, Inc. (NASDAQ:ANGO) on Thursday, April 21.
More news for AngioDynamics, Inc. (NASDAQ:ANGO) were recently published by: Globenewswire.com, which released: “AngioDynamics Appoints Michael C. Greiner as New Chief Financial Officer” on July 25, 2016. Prnewswire.com‘s article titled: “SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating …” and published on September 19, 2016 is yet another important article.
ANGO Company Profile
AngioDynamics, Inc., incorporated on July 30, 1992, designs, makes and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures. The Firm offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.